Thus, future ctDNA plasma testing and identification of PI3K pathway alteration in EGFR-mutant lung cancer patients could classify the patient for a combination treatment of osimertinib and PI3K pathway inhibitor. This evidence concerns the gene EGFR and lung cancer.